2023-08-17 09:30:21
Engineering Techniques spoke with Dr. Jean-Philippe Herbeuval, Research Director at the CNRS and co-founder of Ermium Therapeutics.
Ermium Therapeutics is currently working on a drug candidate to fight once morest excessive production of interferons, which would be involved in the onset of autoimmune diseases. The objective is to lead to a marketing in the next decade. Dr Jean-Philippe Herbeuval, CNRS Research Director and co-founder of Ermium Therapeutics, tells us more regarding the work of this start-up created in 2019.
On the eve of a breakthrough in the treatment of autoimmune diseases, Dr. Jean-Philippe Herbeuval discusses the research carried out by Ermium Therapeutics in the fight once morest the production of interferons, in particular the confirmation of the role of histamine , as well as a similar molecule. The interview also discusses the unexpected effect of positively charged amine molecules on a receptor, CXCR4, to which unwanted cells bind.
Achieving the production of effective molecules without hindering the functioning of the essential CXR4 receptor is thus a challenge taken up by Ermium Therapeutics.
Finally, beyond the treatment of autoimmune diseases such as lupus, Ermium Therapeutics hopes to open the way to other therapeutic applications. Dr. Jean-Philippe Herbeuval outlines for us the future of these promising technologies.
1692294087
#Ermium #Therapeutics #cusp #breakthrough #treatment #autoimmune #diseases #White #paper
